All twenty participants who had signs of metabolic syndrome at baseline and submitted adequate stool samples at four data collection time points were included in the current investigation (Fig. 1), which allowed for comparison of the gut microbial and SCFA profiles before and after the interventions and also between the endpoints of the RS4 and CF (control) interventions. This evidence concerns the gene CFTR and metabolic syndrome.